Skip to main content

Table 1 Characteristics of randomized clinical trials included

From: Omega-3 supplementation in patients with sepsis: a systematic review and meta-analysis of randomized trials

Study Population Intervention Mortality definition Risk of bias Funding
Bower et al. [28]
Multi-centre
USA
ICU patients
(N = 326); stratified by sepsis (N = 44 of 326)
Age 18–80
Enteral administration
Impact versus Osmolyte
NR High Pharmaceutical (Sandoz Nutrition)
Galban et al. [30]
Multi-centre
Spain
ICU patients with sepsis requiring EN (N = 181)
Age > 14 (mean 55.8)
Enteral administration
Impact versus Precitene Hiperproteico
NR High Pharmaceutical (Novartis Nutrition)
Grecu et al. [32]
Single-centre
Romania
ICU and PACU patients with abdominal sepsis requiring PN; 15 of 54 in ICU
Age NR
Parenteral administration
Omegaven + LCT versus LCT alone
ICU Unclear NR
Pontes-Arruda et al. [35]
Single-centre
Brazil
ICU patients with severe sepsis or septic shock requiring MV (N = 103)
Age > 18 (mean 65.1)
Enteral administration
EPA, GLA, antioxidants versus standard formulation
28-day High Pharmaceutical (Abbott Laboratories)
Guo et al. [42]
Single-centre
China
ICU patients with sepsis and APACHE II score >12 (N = 80)
Age 18–70 (mean 40.0)
Parenteral administration
Omega-3 PUFAs versus 20% fat emulsion
28-day High NR
Qu et al. [39]
NR
China
Patients with sepsis and APACHE II score 15–20 (N = 40)
Age 18–65
Parenteral administration
10% omega-3 PUFAs versus standard TPN
28-day Unclear Academic. National Natural Science Foundation of China
Barbosa et al. [43]
Single-centre
Portugal
ICU patients with sepsis predicted to need parenteral nutrition (N = 25)
Age range 32–80
Parenteral administration
Lipoplus + NuTRIflex Special versus NuTRIflex Lipid Special
28-day and 5-day High No external funding
Wu et al. [40]
Single-centre
China
ICU patients with sepsis (N = 60)
Mean age 63.42
Parenteral administration
Omega-3 PUFAs versus 20% LCTs
28-day High NR
Zhao et al. [41]
Single-centre
China
ICU patients with sepsis or septic shock (N = 116)
Mean age 53.3
Parenteral administration
Omegaven versus standard care
28-day Unclear NR
Grau-Carmona et al. [31]
Multi-centre
Spain
ICU patients with sepsis and receiving MV (N = 132)
Age ≥ 18 (mean 63)
Enteral administration
Oxepa versus Ensure Plus
28-day High Pharmaceutical (Abbott Laboratories)
Khor et al. [34]
Single-centre
Taiwan
ICU patients with severe sepsis (N = 28)
Age ≥ 18 (mean 69.3)
Parenteral administration
Omegaven versus normal saline
28-day Unclear NR
Pontes-Arruda et al. [36]
Multi-centre
Brazil
ICU patients with early sepsis requiring EN (N = 106)
Age > 18 (mean 71)
Enteral administration
Oxepa versus Ensure Plus HN
28-day High Pharmaceutical (Abbott Laboratories)
Hosny et al. [25]
Single-centre
Egypt
ICU patients with early sepsis (N = 75)
Age ≥ 18 (mean 52.1)
Enteral administration (oral or NG)
High-dose omega-3 + antioxidants versus low-dose omega-3 + antioxidants versus standard care
28-day High NR
Burkhart et al. [29]
Single-centre
Switzerland
ICU patients with sepsis (N = 50)
Age > 18 (mean 69)
Parenteral administration
Omegaven versus standard care
Median follow-up 109 days High Pharmaceutical (Fresenius Kabi) and academic
Gultekin et al. [38]
Single-centre
Turkey
General Surgery ICU patients with severe sepsis or septic shock requiring TPN (N = 32)
Age ≥ 18 (mean 62.9)
Parenteral administration
Omegaven + ClinOleic—Baxter olive oil emulsion versus olive oil emulsion
NR High NR
Hall et al. [33]
Single-centre
United Kingdom
ICU patients with sepsis (N = 60)
Adults (mean age 64.2)
Parenteral administration
Omegaven versus standard care
28-day and inpatient Unclear Omegaven supplied by Fresenius Kabi; no other financial support
Shirai et al. [37]
Single-centre
Japan
ICU patients with sepsis-induced ARDS receiving MV (N = 46)
Age > 18 (mean 72.5)
Enteral administration
Oxepa versus Ensure Liquid
60-day High NR
  1. APACHE II Acute Physiology and Chronic Health Evaluation II, ARDS acute respiratory distress syndrome, EN enteral nutrition, EPA eicosapentaenoic acid, GLA gamma linolenic acid, ICU intensive care unit, LCT long-chain triglycerides, MV mechanical ventilation, NG nasogastric, NR non-reported, PN parenteral nutrition, PUFAs polyunsaturated fatty acids, TPN total parenteral nutrition